Stroke Trials Registry

Dipyridamole
Persantine® Aggrenox®

Action
Platelet aggregation inhibitor

Status
Dipyridamole is US FDA approved as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement. Aggrenox (extended-release dipyridamole 200mg/aspirin 25mg) was approved by the US FDA 11/99 for prevention of recurrent strokes and TIAs.

Trial(s)
= Ongoing
= Completed

AICLA Controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia

AMBDAP Dual antiplatelet therapy in the acute phase following stroke and transient ischaemic attack (TIA): which is the best regimen?

Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks

CADISS Cervical Artery Dissection In Stroke Study: Feasibility Phase.

Controlled trial of dipyridamole in cerebral vascular disease

Dipyridamole and postoperative ischemic deficits in aneurysmal subarachnoid hemorrhage

ESPRIT European / Australasian Stroke Prevention in Reversible Ischaemia Trial

ESPS-2 European Stroke Prevention Study

Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in stroke prevention

Pentoxifylline and antiaggregants in recent transient ischemic attacks

Pentoxifylline versus conventional antiaggregants in secondary stroke prevention

Persantine Aspirin Trial

PRoFESS Prevention Regimen For Effectively avoiding Second Strokes

RCS Recurrent Carotid Stenosis

RESPECT Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment

TACET The Austrian Paradoxical Cerebral Embolism Trial

TARDIS Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke

Web Links and Publications

Note: This is an abridged publications list. Click on a clinical trial name above for a full list of publications resulting from that trial.

Aggrenox® Web Site (Boehringer Ingelheim Pharmaceuticals).

Boehringer Ingelheim Web Site.

Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin (Cochrane Review).
Cochrane Database Syst Rev. 2001;4:CD001342.

Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.
Cochrane Database Syst Rev. 2001;1:CD001938. Review.

ESPRIT: Mild Anticoagulation, Acetylsalicylic Acid Plus Dipyridamole or Acetylsalicylic Acid Alone After Cerebral Ischaemia of Arterial Origin.
European Stroke Conference

Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin.
Cerebrovasc Dis. 2000 Mar;10(2):147-150.

Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy.
Ann Intern Med 1992 May 1;116(9):731-6.

European Stroke Prevention Study. ESPS Group.
Stroke 1990 Aug;21(8):1122-1130

Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks.
Acta Neurol Scand 1987 Dec;76(6):413-21.

Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group.
Stroke 1985 May-Jun;16(3):406-15.

Dipyridamole and postoperative ischemic deficits in aneurysmal subarachnoid hemorrhage.
: J Neurosurg 1985 Nov;63(5):699-703.

"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.
Stroke 1983 Jan-Feb;14(1):5-14.

Controlled trial of dipyridamole in cerebral vascular disease.
Br Med J 1969 Mar 8;1(644):614-5

UID: 15